Browsing Pathways
Showing 161 -
170 of 605359 pathways
SMPDB ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0174640View Pathway |
Acrivastine Predicted Metabolism PathwayMetabolites of sildenafil are predicted with biotransformer.
|
|
||
SMP0128680View Pathway |
Acrothecium robustum Drug Metabolism |
|
||
SMP0130520View Pathway |
Activated charcoal Drug MetabolismActivated charcoal is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Activated charcoal passes through the liver and is then excreted from the body mainly through the kidney.
|
|
||
SMP0144399View Pathway |
Activated charcoal Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0063764View Pathway |
Activation of cAMP-dependent protein kinase, PKAcAMP dependent protein kinase is a signalling molecule, found in the nucleus and cytoplasm of cells. Cellular regulation and signal transduction in eukaryotic cells is driven by the phosphorylation of proteins. cAMP dependent protein kinase is created as an active enzyme, which is made possible by a fully phosphorylated activation loop.
|
Protein
|
|
|
SMP0000749View Pathway |
Activation of PKC Through G Protein-Coupled ReceptorG protein-coupled receptors sense stimuli outside the cell and transmit signals across the plasma membrane. Activation of protein kinase C (PKC) is one of the common signaling pathways. When a class of GPCRs are activated by a ligand, they activate Gq protein to bind GTP instead of GDP. After the Gq becomes active, it activates phospholipase C (PLC) to cleave the membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG). IP3 can bind Ins3P receptor to open calcium channel by diffusion from cytoplasm to ER. Activated calcium channel will release the calcium from ER into cytoplasm. Calcium can activate the kinase activity of PKC.
|
Signaling
|
||
SMP0130184View Pathway |
Actoxumab Drug Metabolism |
|
||
SMP0000344View Pathway |
Acute Intermittent PorphyriaAcute intermittent porphyria (AIP), also called Swedish porphyria, is a rare inborn error of metabolism (IEM) and autosomal dominant disorder of heme biosynthesis caused by a defective HMBS gene. The HMBS gene codes for the protein hydroxymethylbilane synthase (porphobilinogen deaminase) which catalyzes the synthesis of porphobilinogen into hydroxymethylbilane. This disorder is characterized by a large accumulation of 5-aminolevulinic acid or porphobilinogen in both urine and serum. Most patients are asymptomatic between attacks. Symptoms of the disorder include abdominal pain, constipation, vomiting, hypertension, muscle weakness, seizures, delirium, coma, and depression. Treatment involves undertaking a high-carbohydrate diet and, during severe attacks, a glucose 10% infusion. It is estimated that AIP affects 5.9 per 1 000 000 people.
|
Disease
|
|
|
SMP0125644View Pathway |
Acute Intermittent PorphyriaAcute intermittent porphyria (AIP), also called Swedish porphyria, is a rare inborn error of metabolism (IEM) and autosomal dominant disorder of heme biosynthesis caused by a defective HMBS gene. The HMBS gene codes for the protein hydroxymethylbilane synthase (porphobilinogen deaminase) which catalyzes the synthesis of porphobilinogen into hydroxymethylbilane. This disorder is characterized by a large accumulation of 5-aminolevulinic acid or porphobilinogen in both urine and serum. Most patients are asymptomatic between attacks. Symptoms of the disorder include abdominal pain, constipation, vomiting, hypertension, muscle weakness, seizures, delirium, coma, and depression. Treatment involves undertaking a high-carbohydrate diet and, during severe attacks, a glucose 10% infusion. It is estimated that AIP affects 5.9 per 1 000 000 people.
|
Disease
|
|
|
SMP0128033View Pathway |
ACY001 Drug Metabolism |
|
Showing 161 -
170 of 65006 pathways